View More Recent Stories
-
Monte Rosa Therapeutics (GLUE) Announces Global License Agreement with Novartis (NVS) to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
-
Novartis (NVS) call put ratio 1 call to 4.1 puts into quarter results
-
TD Cowen Reiterates Hold Rating on Novartis (NVS)
-
Novartis' (NVS) Kisqali Approved by FDA to Reduce Risk of Recurrence in People With HR+/HR2- Early Breast Cancer
-
BofA Securities Downgrades Novartis (NOVN:SW) (NVS) to Neutral
-
BMO Capital Reiterates Market Perform Rating on Novartis (NVS)
-
Erste Group Upgrades Novartis (NVS) to Buy, 'currently valued below the sector average despite the good growth prospects'
-
Voyager Therapeutics (VYGR) Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
-
Goldman Sachs Downgrades Novartis (NVS) to Neutral
-
Goldman Sachs Downgrades Novartis (NOVN:SW) (NVS) to Neutral
-
Jefferies Downgrades Novartis (NVS) to Hold
-
Jefferies Downgrades Novartis (NOVN:SW) (NVS) to Hold
-
These 5 stocks are new additions to Bernstein's CEO Value Index
-
Novartis (NVS) twice-yearly Leqvio demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
-
Novartis (NVS) and Lindy Biosciences Enter Licensing and Collaboration Agreement
-
FDA Approved Novartis' (NVS) fabhalta for Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy
-
Novartis (NOVN:SW) (NVS) PT Raised to CHF86 at Berenberg
-
Novartis (NVS) PT Raised to $118 at BMO Capital
-
Increasing unusual put option volume: NVS DPZ HUMA ELV CMG
-
Novartis (NVS) Tops Q2 EPS by 13c; offers outlook
-
Increasing unusual put option volume: NVS RF QS URBN FIVE CAG LNTH CPB SABR HUBS OMF
-
Novartis (NOVN:SW) (NVS) PT Raised to CHF97 at Citi
-
Increasing unusual put volume: CMG MAXN NVS SAVA ENB EOSE
